Genenta Science Authorizes €300M Capital Raise, Reverse Split

Genenta Science S.p.A. held an Extraordinary Shareholders’ Meeting where shareholders approved significant corporate actions. The Board was granted authority to increase share capital by up to €300,000,000 and issue up to 120,000,000 new ordinary shares or convertible bonds. Additionally, shareholders authorized a reverse stock split at a ratio between 1-for-10 and 1-for-20, intended to help maintain Nasdaq's minimum bid price requirement. A proposal to change the company's corporate name was deferred to a reconvened meeting on September 10, 2026, for further evaluation.